<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915252</url>
  </required_header>
  <id_info>
    <org_study_id>101010</org_study_id>
    <nct_id>NCT00915252</nct_id>
  </id_info>
  <brief_title>Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)</brief_title>
  <acronym>AML-AZA</acronym>
  <official_title>A Randomized, Multi-center Phase II Trial to Assess the Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of the study is to determine, whether the addition of 5-azacytidine to
      standard chemotherapy in elderly patients with newly diagnosed AML improves treatment results
      (event free survival).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median Event Free Survival (EFS) of all AML patients</measure>
    <time_frame>continously up to 12 months after start of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median event free survival of AML patients with different cytogenetic and molecular risk groups</measure>
    <time_frame>continously up to 12 months after study start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival of all AML patients</measure>
    <time_frame>continously up to 12 month after start of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival of AML patients with different cytogenetic and molecular risk groups</measure>
    <time_frame>continously up to 12 month after start of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse free survival</measure>
    <time_frame>continously up to 12 months after start of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>5-azacytidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients enrolled in this arm will receive standard induction and consolidation chemotherapy preceded by 5-azacytidine. These patients will additionally receive maintenance therapy with 5-azacytidine for one year after start of induction therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients enrolled in this arm will receive standard chemotherapy treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
    <description>Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:
During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).
During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy.</description>
    <arm_group_label>5-azacytidine</arm_group_label>
    <other_name>5-azacytidine</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine</intervention_name>
    <description>Induction therapy:
Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7
Consolidation therapy:
AraC 1g/m² twice a day on day 1,3,5</description>
    <arm_group_label>standard chemotherapy</arm_group_label>
    <other_name>Ara-C</other_name>
    <other_name>Daunoblastin</other_name>
    <other_name>DaunoXome</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-cell</other_name>
    <other_name>Udicil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed AML (except APL) according to the FAB or WHO
             classification, including AML evolving from MDS or other hematological diseases and
             AML after previous cytotoxic therapy or radiation (secondary AML).

          -  Bone marrow aspirate or biopsy must contain ≥ 20% blasts of all nucleated cells or
             differential blood count must contain ≥ 20% blasts. In AML FAB M6 ≥ 30% of
             non-erythroid cells in the bone marrow must be leukemic blasts. In AML defined by
             cytogenetic aberrations the proportion of blasts may be &lt; 20%.

          -  Age ≥ 61 years

          -  Informed consent, personally signed and dated to participate in the study

          -  Male patients enrolled in this trial must use adequate barrier birth control measures
             during the course of the 5-azacytidine treatment and for at least 3 months after the
             last administration of 5-azacytidine.

        Exclusion Criteria:

          -  Patients who are not eligible for standard chemotherapy as described in chapter 5.2
             and 5.3

          -  Hyperleukocytosis (leukocytes &gt; 20,000/µl) at study entry. These patients should be
             treated with hydroxyurea or receive leukocytapheresis treatment (if leukocytes &gt;
             100,000/µl) according to routine practice and entered into the study when leukocyte
             counts below 20,000/µl are reached. This applies only for the controlled part of the
             study.

          -  Patients with initial hyperleukocytosis above 20,000/µl can only be enrolled into the
             controlled part of the study, but not in the run-in dose finding part.

          -  Known central nervous system manifestation of AML

          -  Cardiac Disease: Heart failure NYHA class 3 or 4; unstable coronary artery disease (MI
             more than 6 months prior to study entry is permitted); serious cardiac ventricular
             arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted)

          -  Chronically impaired renal function (creatinin clearance &lt; 30 ml / min)

          -  Inadequate liver function (ALT and AST ≥ 2.5 x ULN) if not caused by leukemic
             infiltration

          -  Total bilirubin ≥ 1.5 x ULN if not caused by leukemic infiltration

          -  Known HIV and/or hepatitis C infection

          -  Evidence or history of severe non-leukemia associated bleeding diathesis or
             coagulopathy

          -  Evidence or recent history of CNS disease, including primary or metastatic brain
             tumors, seizure disorders

          -  Uncontrolled active infection

          -  Concurrent malignancies other than AML with an estimated life expectancy of less than
             two years

          -  History of organ allograft

          -  Hypersensitivity to cytarabine (not including drug fever or exanthema), daunorubicin,
             azacytidine or mannitol

          -  Previous treatment of AML except hydroxyurea and up to 2 days of ≤100 mg/m2/d
             cytarabine

          -  Previous therapy with 5-azacytidine (i.e. for an antecedent myelodysplastic syndrome)

          -  Patients with investigational drug therapy outside of this trial during or within 4
             weeks of study entry should be discussed with the study office whether study
             participation is possible

          -  Any severe concomitant condition, which makes it undesirable for the patient to
             participate in the study or which could jeopardize compliance with the protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>61 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carsten Müller-Tidow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Münster, Medizinische Klinik A</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RWTH Aachen, Medizinische Klinik IV</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sozialstiftung Bamberg, Klinikum am Bruderwald, Med. Klinik V</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bayreuth, Medizinische Klinik IV</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Benjamin Franklin, Universitätsmedizin Berlin, Medizinische Klinik III</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städt. Kliniken Bielefeld gem. GmbH, Klinikum Mitte, Klinik für Hämatologie, Onkologie, Palliativmedizin</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz, Krankenhaus Küchenwald, Klinik für Innere Medizin III</name>
      <address>
        <city>Chemnitz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Katholische Krankenhaus Duisburg</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Erlangen, Medizinische Klinik 5</name>
      <address>
        <city>Erlangen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Hämatologie</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann Wolfgang Goethe-Universität Frakfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik St. Georg, Hämatologische Abteilung</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Bernward Krankenhaus Hildesheim, Medizinische Klinik II</name>
      <address>
        <city>Hildesheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH, Med. Klinik I</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftungsklinikum Mittelrhein, Hämatologie/ Onkologie</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johannes Gutenberg-Universität Mainz Klinikum, III. Medizinische Klinik und Poliklinik</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Phillips Universität Marburg, Fachbereich 20, ZIM</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar, III. Medizinische Klinik</name>
      <address>
        <city>Muenchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Medizinische Klinik und Poliklinik A</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg, Medizinische Klinik 5</name>
      <address>
        <city>Nurnberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Osnabrück, Klinik für Onkologie, Hämatologie, Immunologie</name>
      <address>
        <city>Osnabruck</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg, Klinik und Poliklinik für Innere Medizin I</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus, Zentrum für Innere Medizin</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen, Innere Medizin I</name>
      <address>
        <city>Trier</city>
        <zip>2920</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Horst-Schmidt-Kliniken</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>azacitidine</keyword>
  <keyword>elderly</keyword>
  <keyword>demethylating agent</keyword>
  <keyword>flt3</keyword>
  <keyword>AML</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

